David Harrison

413 total citations
18 papers, 269 citations indexed

About

David Harrison is a scholar working on Molecular Biology, Immunology and Surgery. According to data from OpenAlex, David Harrison has authored 18 papers receiving a total of 269 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 3 papers in Immunology and 2 papers in Surgery. Recurrent topics in David Harrison's work include Inflammasome and immune disorders (8 papers), Sphingolipid Metabolism and Signaling (4 papers) and Eicosanoids and Hypertension Pharmacology (2 papers). David Harrison is often cited by papers focused on Inflammasome and immune disorders (8 papers), Sphingolipid Metabolism and Signaling (4 papers) and Eicosanoids and Hypertension Pharmacology (2 papers). David Harrison collaborates with scholars based in United States, United Kingdom and France. David Harrison's co-authors include Alan P. Watt, Valérie Reader, John R. Doedens, Mark G. Bock, Pamela J. Smolak, Christopher A. Gabel, Richard Davenport, Ralph E. Gianelly, Keith Cohn and Andy Billinton and has published in prestigious journals such as Nature, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

David Harrison

15 papers receiving 245 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Harrison United States 9 140 54 36 34 25 18 269
Jie Shi China 11 168 1.2× 19 0.4× 29 0.8× 21 0.6× 15 0.6× 27 415
Wenwei Luo China 11 176 1.3× 39 0.7× 56 1.6× 40 1.2× 16 0.6× 29 373
K. Wakitani Japan 11 192 1.4× 157 2.9× 45 1.3× 41 1.2× 18 0.7× 15 475
Toshiki Kurosawa Japan 12 91 0.7× 22 0.4× 19 0.5× 22 0.6× 10 0.4× 20 301
Claudia Carmone Netherlands 8 164 1.2× 19 0.4× 70 1.9× 62 1.8× 9 0.4× 14 307
Stephan Sickinger Austria 6 197 1.4× 59 1.1× 38 1.1× 17 0.5× 5 0.2× 6 341
Oh-Hoon Kwon South Korea 7 129 0.9× 18 0.3× 76 2.1× 22 0.6× 28 1.1× 11 243
Feng Yuan China 10 108 0.8× 27 0.5× 33 0.9× 15 0.4× 8 0.3× 18 226
Anna‐Kaisa Ruotsalainen Finland 7 173 1.2× 27 0.5× 29 0.8× 55 1.6× 12 0.5× 17 297

Countries citing papers authored by David Harrison

Since Specialization
Citations

This map shows the geographic impact of David Harrison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Harrison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Harrison more than expected).

Fields of papers citing papers by David Harrison

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Harrison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Harrison. The network helps show where David Harrison may publish in the future.

Co-authorship network of co-authors of David Harrison

This figure shows the co-authorship network connecting the top 25 collaborators of David Harrison. A scholar is included among the top collaborators of David Harrison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Harrison. David Harrison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Harrison, David, Andy Billinton, Mark G. Bock, et al.. (2025). Profile of NT-0527, a brain penetrant NLRP3 Inflammasome inhibitor suitable as an in vivo tool compound for neuroinflammatory disorders. RSC Medicinal Chemistry. 16(11). 5318–5332.
2.
Smolak, Pamela J., MyTrang Nguyen, John R. Doedens, et al.. (2024). Target Cell Activation of a Structurally Novel NOD-Like Receptor Pyrin Domain-Containing Protein 3 Inhibitor NT-0796 Enhances Potency. Journal of Pharmacology and Experimental Therapeutics. 388(3). 798–812. 9 indexed citations
3.
4.
Thornton, Peter, Valérie Reader, Zsofia Digby, et al.. (2024). Reversal of High Fat Diet-Induced Obesity, Systemic Inflammation, and Astrogliosis by the NLRP3 Inflammasome Inhibitors NT-0249 and NT-0796. Journal of Pharmacology and Experimental Therapeutics. 388(3). 813–826. 28 indexed citations
5.
Doedens, John R., et al.. (2024). The ester-containing prodrug NT-0796 enhances delivery of the NLRP3 inflammasome inhibitor NDT-19795 to monocytic cells expressing carboxylesterase-1. Biochemical Pharmacology. 227. 116455–116455. 3 indexed citations
6.
Harrison, David. (2024). Brain Penetrant NLRP3 Inhibitors: The Discovery of a Panacea?. Journal of Medicinal Chemistry. 67(23). 20776–20779. 2 indexed citations
7.
Harrison, David, Andy Billinton, Mark G. Bock, et al.. (2023). Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory Disorders. Journal of Medicinal Chemistry. 66(21). 14897–14911. 35 indexed citations
8.
Harrison, David, Mark G. Bock, John R. Doedens, et al.. (2022). Discovery and Optimization of Triazolopyrimidinone Derivatives as Selective NLRP3 Inflammasome Inhibitors. ACS Medicinal Chemistry Letters. 13(8). 1321–1328. 15 indexed citations
9.
Ahmed, Saleh A., Andrew Ayscough, Richard Davenport, et al.. (2017). 1,2,4-Triazolo-[1,5-a]pyridine HIF Prolylhydroxylase Domain-1 (PHD-1) Inhibitors With a Novel Monodentate Binding Interaction. Journal of Medicinal Chemistry. 60(13). 5663–5672. 28 indexed citations
10.
Davenport, Richard, Johannes Grosse, Kazumasa Ogawa, et al.. (2014). Identification of a novel GPR81-selective agonist that suppresses lipolysis in mice without cutaneous flushing. European Journal of Pharmacology. 727. 1–7. 46 indexed citations
11.
Bissaro, Bastien, Michel Dion, Olivier Saurel, et al.. (2013). Engineering transglycosidase activity into a GH51 α-l-arabinofuranosidase. New Biotechnology. 30(5). 536–544. 27 indexed citations
12.
Harrison, David & Robert A. Kates. (1982). Pharmacologic counter measures minimizing post-space flight orthostatic intolerance. [bed rest, drug disposition, and physiological function. 1 indexed citations
13.
Sinclair, Alison J., William H. Barry, & David Harrison. (1972). The Effect of Acetylcholine on Single Embryonic Chick Ventricle Cells. Experimental Biology and Medicine. 139(1). 165–168. 5 indexed citations
14.
Harrison, David, et al.. (1971). Myocardial Hypertrophy Resulting from Low Dosage Isoproterenol Administration in Rats. Experimental Biology and Medicine. 136(1). 268–270. 39 indexed citations
15.
Gianelly, Ralph E., et al.. (1969). The Circulatory Effects of Isoproterenol, Acetylstrophanthidin, and Volume Loading in Acute Pericardial Tamponade. Cardiovascular Research. 3(3). 299–305. 21 indexed citations
16.
Harrison, David, et al.. (1967). Action of Isoproterenol on Heart Cells in Tissue Culture.. Experimental Biology and Medicine. 124(1). 122–126. 3 indexed citations
17.
Harrison, David, Charles A. Chidsey, & E. Braunwald. (1965). STUDIES ON THE MECHANISM OF ACTION OF METARAMINOL (ARAMINE). Survey of Anesthesiology. 9(1). 30???31–30???31. 1 indexed citations
18.
Harrison, David. (1962). Progress in Biochemistry. Nature. 194(4826). 324–324. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jie Shi Breakdown of academic impact, for papers by Wenwei Luo Breakdown of academic impact, for papers by K. Wakitani Breakdown of academic impact, for papers by Toshiki Kurosawa Breakdown of academic impact, for papers by Claudia Carmone Breakdown of academic impact, for papers by Stephan Sickinger Breakdown of academic impact, for papers by Oh-Hoon Kwon Breakdown of academic impact, for papers by Feng Yuan Breakdown of academic impact, for papers by Anna‐Kaisa Ruotsalainen
Rankless by CCL
2026